CD5-targeting NK cell therapy for blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new kind of immune cell therapy (NK cells) that are made to attack cancer cells carrying the CD5 marker. You will have a short course of chemotherapy before the infusion to help the cells work. It is for people with certain blood cancers that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer cells must have at least 30% of a marker called CD5, as shown by a recent lab test.
- You must have one of these blood cancers that has come back after at least 2 treatments: T-cell lymphoma, T-cell leukemia, CLL/SLL, or mantle cell lymphoma.
- You must be between 12 and 80 years old and generally able to care for yourself (performance score above 50%).
- Your heart, lungs, liver, and kidneys must be working well enough (specific lab and imaging tests will check this).
- You cannot have a serious, uncontrolled infection, active hepatitis B or C, or uncontrolled HIV.
- You must agree to use effective birth control during the study and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using specially engineered immune cells (NK cells) that target the CD5 protein found on certain T-cell blood cancers. The cells are given after a short course of chemotherapy to help them work better. It may be an option for people with aggressive T-cell cancers that have not responded to standard therapy.
This trial tests a new type of cell therapy for people with certain types of lymphoma (Hodgkin or diffuse large B-cell) that did not respond fully to first treatment or came back within a year. The therapy uses modified natural killer (NK) cells that target a protein called CD70 found on the cancer cells.
This trial tests a new type of immune cell therapy using cord blood cells that are grown to attack cancer cells. It is for people with certain blood cancers (lymphoma or acute lymphoblastic leukemia) that have come back or not responded to standard treatments.
This trial tests a new immune cell therapy (engineered NK cells) for people with certain blood cancers like AML, MDS, or CMML that have not responded to standard treatments. The therapy aims to help your immune system attack cancer cells, and is given after a short course of chemotherapy.
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
This trial tests a new type of immune cell (NK cell) that has been engineered to target a protein called PRAME found on some cancer cells. It is for people with certain types of blood cancer (AML, MDS, or CMML) that have come back or not responded to treatment.
Hear when a new Hematological Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.